Installation of 1000th Simulation System

By

Regulatory News | 04 Mar, 2021

Updated : 07:00

RNS Number : 0887R
Intelligent Ultrasound Group PLC
04 March 2021
 

4 March 2021

Intelligent Ultrasound Group plc

(the "Company")

 

Installation of 1000th Simulation System

Point of Care ultrasound scenario trainer installed at Ohio State University College of Medicine

 

Intelligent Ultrasound Group plc (AIM: IUG), the ultrasound artificial intelligence (AI) software and simulation company, announces that they have recently installed their 1000th ultrasound simulation system, a BodyWorks Eve PoCUS and Covid-19 training simulator, into one of the leading medical institutions in North America.

 

The installation, at the Clinical Skills Education and Assessment Center of the Ohio State University College of Medicine ("OSUCM"), will allow them to expand their education reach beyond echocardiography and into point of care ultrasound and reduce their reliance on live models.

 

Bodyworks™ Eve is the Company's ultra-realistic female patient simulator designed for interactive Point of Care Ultrasound (PoCUS) scenario training, as well as Covid-19 training for frontline clinicians.

 

The addition of the Bodyworks™ Eve simulator to OSUCM's existing HeartWorks™ simulation system will allow the medical school to expand their existing ultrasound training for medical students to include full chest, abdominal, pelvic, and early OB (obstetric) critical care.

 

Ian Whittaker, COO of Intelligent Ultrasound Group plc, commented: "We are delighted to reach this significant sales milestone. North America is a key market for our range of ultrasound training simulators and  the Ohio State University College of Medicine is acknowledged as one of the top teaching institutions in the US."

 

For further information, please contact:

 

Intelligent Ultrasound Group plc 

www. intelligentultrasound.com

Stuart Gall, CEO 
Helen Jones, CFO

Tel: +44 (0)29 2075 6534 



Cenkos Securities - Nominated Advisor and Broker

Tel:  +44 (0)20 7397 8900 

Giles Balleny (Corporate Finance)


Michael Johnson / Julian Morse (Sales) 




Walbrook PR 

Tel: +44 (0)20 7933 8780 or intelligentultrasound@walbrookpr.com 

Anna Dunphy / Paul McManus 

Mob: +44 (0)7876 741 001 / Mob: +44 (0)7980 541 893

 



 

About Intelligent Ultrasound Group

 

Intelligent Ultrasound (AIM: IUG) develops artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market and hi-fidelity virtual reality simulators for the ultrasound training market. Based in Cardiff in the UK and Atlanta in the US, the Group operates two divisions:

 

Clinical AI Division

 

Focusses on developing deep learning-based algorithms to make ultrasound machines smarter and more accessible. Products in the market include ScanNav Assist, which uses machine-learning based algorithms to automatically identify and grade ultrasound images. GE Healthcare's SonoLyst software on their Voluson SWIFT ultrasound machine incorporates the ScanNav Assist AI technology and has received 510(k) clearance from the FDA for sale in the USA. SonoLyst is the world's first fully integrated AI tool that recognises the 20 views recommended by the International Society of Ultrasound in Obstetrics and Gynaecology mid-trimester practice guidelines for fetal imaging.

 

Products in development include ScanNav Anatomy PNB, which aims to simplify ultrasound-guided needling by providing the user with real-time AI-based anatomy highlighting software for a range of medical procedures. ScanNav Anatomy has been submitted for CE and FDA regulatory approval.

 

Simulation Division 

 

Focusses on hi-fidelity ultrasound education and training through simulation.  Its three main products are the ScanTrainer OBGYN training simulator, the HeartWorks echocardiography training simulator and the BodyWorks Eve Point of Care and Emergency Medicine training simulator. To date over 1,000 simulators have been sold to over 600 medical institutions around the world.

 

www.intelligentultrasound.com

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAJJMRTMTMMBAB

Last news